Gilead's Stock Price is Expected to Rise to $160，Gilead’s $5 Billion Tubulis Deal Could Reshape the Cancer Drug Market of America

TradingKey - Gilead Sciences has confirmed its intention to acquire Tubulis (Germany) for a maximum value of up to $5 billion dollars. This acquisition is expected to add considerable strength to Gilead's pipeline for oncology products and provide them with greater access to the developing market fo